Wednesday, February 10, 2010, 1:10PM AEST - The Australian Stockmarket closes in 2 hours and 55 minutes.
To create a watchlist or portfolio of shares, Register

Exelixis, Inc. (EXEL)

8:00AM AEST: 6.42 USD  Up 0.32 (5.25%)  
 MORE ON EXEL 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Exelixis, Inc. (NasdaqNM:EXEL) Delayed quote dataEdit
Last Trade:6.42 USD
Trade Time: 8:00AM AEST
Change:Up 0.32 (5.25%)
Prev Close:6.10
Open:6.19
Bid:5.60 x 100
Ask:6.74 x 1000
1y Target Est:6.18
Day's Range:6.12 - 6.43
52wk Range:4.09 - 8.00
Volume:743,335
Avg Vol (3m):949,464
Market Cap:689.42M
P/E (ttm):N/A
EPS (ttm):-1.35
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add EXEL to Portfolio   Download Data

 HEADLINES 
Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO and Investor Conference
Business Wire (Fri, Feb 5)
Glaxo Brings Home the Bacon
at Motley Fool (Fri, Feb 5)
How to Make a Billion Bucks in Biotech
at Motley Fool (Fri, Jan 29)
Fearful Stocks for Greedy Investors
at Motley Fool (Wed, Jan 27)
EXELIXIS INC Files SEC form 8-K, Other Events
EDGAR Online (Sat, Jan 16)
3 Reasons to Sell Sequenom Today
at Motley Fool (Sat, Jan 16)
Exelixis: Volatility Expected to Subside in 2010
at Seeking Alpha (Tue, Jan 12)
EXELIXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio
EDGAR Online (Thu, Dec 24)
Exelixis, Inc.: Warming Up or Cooling Off?
at Motley Fool (Wed, Dec 23)
Goodman named to Texas drug company board
at bizjournals.com (Wed, Dec 16)
EXELIXIS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Sat, Dec 12)
More Headlines for EXEL...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.24
EPS Est (in 2 years) (Dec-10) :-1.09
Avg Rec (current)*:2.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which dri...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices